홈 › 비소세포폐암 › 오클라호마 › Oklahoma City
OK Oklahoma City의 비소세포폐암 임상 시험
비소세포폐암 관련 연구 28개가 Oklahoma City 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
피험자 모집 중3상
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
피험자 모집 중3상
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
- Integris Cancer Institute of Oklahoma, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
피험자 모집 중1/2상
- University of Oklahoma, Oklahoma City
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
피험자 모집 중3상
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
피험자 모집 중3상
- Local Institution - 0418, Oklahoma City
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
피험자 모집 중3상
- Hightower Clinical, LLC ( Site 0084), Oklahoma City
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
피험자 모집 중2상
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
피험자 모집 중2/3상
- INTEGRIS Cancer Institute of Oklahoma, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
피험자 모집 중1/2상
- University of Oklahoma, Oklahoma City
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
피험자 모집 중3상
- Clinical Study Site, Oklahoma City
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
피험자 모집 중1/2상
- OU Health Stephenson Cancer Center, Oklahoma City
A Phase 1/1b Study of IAM1363 in HER2 Cancers
피험자 모집 중1상
- OU Health Stephenson Cancer Center, Oklahoma City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
피험자 모집 중3상
- University of Oklahoma Health Sciences Center, Oklahoma City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
피험자 모집 중1/2상
- University of Oklahoma - Health Sciences Center, Oklahoma City
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
피험자 모집 중3상
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
피험자 모집 중1상
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
피험자 모집 중관찰 연구
- Mercy Hospital - OKC, Oklahoma City
Study of XB010 in Subjects With Solid Tumors
피험자 모집 중1상
- Stephenson Cancer Center, Oklahoma City
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
피험자 모집 중1상
- OU Stephenson Cancer Center, Oklahoma City
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
피험자 모집 중2상
- University of Oklahoma Health Sciences Center, Oklahoma City
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
피험자 모집 중1/2상
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
피험자 모집 중2상
- University of Oklahoma Health Sciences Center, Oklahoma City
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
피험자 모집 중2/3상
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Southwest Medical Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
피험자 모집 중2상
- University of Oklahoma Health Sciences Center, Oklahoma City
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
피험자 모집 중관찰 연구
- Mercy Hospital Oklahoma City, Oklahoma City
GEMINI-NSCLC: NSCLC Biomarker Study
피험자 모집 중관찰 연구
- Hightower Clinical, Oklahoma City
- Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
피험자 모집 중1상
- Dren Investigational Site, Oklahoma City
A Study of NX-1607 in Adults With Advanced Malignancies
피험자 모집 중1상
- University of Oklahoma, Oklahoma City
다른 도시의 비소세포폐암 시험
- Houston, TX연구 145개
- New York City, NY연구 121개
- Arlington, VA연구 104개
- Nashville, TN연구 97개
- Boston, MA연구 90개
- Los Angeles, CA연구 87개
- St. Louis, MO연구 73개
- Chicago, IL연구 61개
- Baltimore, MD연구 60개
- San Antonio, TX연구 59개
- Columbus, OH연구 57개
- Washington, DC연구 55개
Oklahoma City의 다른 연구
- 난소암연구 28개
- 자궁내막암연구 25개
- 대장직장암연구 22개
- 전립선암연구 21개
- 폐암연구 19개
- 유방암연구 17개
- 전이성 암연구 16개
- 암 (전체)연구 14개
- 급성 골수성 백혈병연구 14개
- 두경부 편평세포암연구 13개
- 방광암연구 11개
- 췌장암연구 11개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.